Search

Zentalis Pharmaceuticals Inc

Slēgts

3.7 -1.6

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.65

Max

3.79

Galvenie mērījumi

By Trading Economics

Ienākumi

-42M

-78M

EPS

-0.59

Darbinieki

106

EBITDA

-42M

-77M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+132.37% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 6. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

25M

356M

Iepriekšējā atvēršanas cena

5.3

Iepriekšējā slēgšanas cena

3.7

Zentalis Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 31. aug. 23:56 UTC

News

Array Technologies has acquired Affordable Wire Management, enhancing its portfolio and growth potential. Shares are trading slightly higher in after-market hours.

2026. g. 31. aug. 23:56 UTC

MannKind Corp shares are lower in after-market trading, continuing a trend observed over the past four sessions amid rising oil prices and inflation concerns.

2026. g. 31. aug. 23:56 UTC

Correlated Moves

Regal Rexnord Corp shares are higher in after-market trading, reflecting a cumulative return of 0.44% since Monday's close amid similar trends from Eaton Corporation PLC.

2026. g. 31. aug. 23:56 UTC

Schrodinger Inc shares are higher in after-hours trading, influenced by rising oil prices and inflation concerns ahead of the Federal Reserve meeting.

2026. g. 31. aug. 23:56 UTC

Mosaic Co's shares are lower in after-market hours, reflecting inflation concerns from rising oil prices ahead of the Federal Reserve meeting.

2026. g. 31. aug. 23:56 UTC

TransDigm Group Inc shares are lower in after-market hours. No specific news was identified to explain the decline amid overall weak market performance.

2026. g. 31. aug. 23:56 UTC

News

Frontier Group Holdings plans to terminate leases for 13 A320neo aircraft, leading to anticipated charges of $60 million to $80 million. Shares are lower in after-market hours.

2026. g. 31. aug. 23:56 UTC

Exelon Corp shares are lower in after-market trading, following fluctuations since Monday's close. Rising oil prices and inflation concerns influence broader market sentiment.

2026. g. 31. aug. 23:56 UTC

Shell PLC shares are lower in after-market trading, following a slight decline since Monday's close. Oil prices have risen, impacting broader market sentiment.

2026. g. 31. aug. 23:56 UTC

abrdn Physical Palladium Shares ETF traded roughly flat after-market hours, with no specific news identified. Global equity indices are mixed amid inflation concerns.

2026. g. 31. aug. 23:52 UTC

Japan's Q2 2026 Capital Spending YoY forecasted to rise only 0.2%, signaling subdued private investment growth amid cautious market sentiment.

2026. g. 31. aug. 23:52 UTC

South Korea's S&P Global Manufacturing PMI release on September 1 faces cautious market sentiment amid rising oil prices and inflation concerns.

2026. g. 31. aug. 23:52 UTC

Federal Reserve Chair Kevin Warsh's hawkish remarks boost interest rate hike expectations to 60-65% amid rising inflation concerns and geopolitical tensions.

2026. g. 31. aug. 23:52 UTC

ISM Manufacturing Employment Data Release on September 1, 2026, Sparks Caution Amid Inflation Concerns and Fed Rate Hike Speculation.

2026. g. 31. aug. 23:52 UTC

ISM Manufacturing PMI Release on September 1 Expected to Show Continued Growth Amid Geopolitical Tensions and Fed Rate Hike Speculation.

2026. g. 31. aug. 23:52 UTC

Australia's Balance of Trade data set for September 3, 2026, anticipates a AUD 1.4 billion surplus amid mixed market sentiment and geopolitical tensions affecting investor confidence.

2026. g. 31. aug. 23:52 UTC

JOLTs Job Openings Report on September 1 Expected to Influence Fed Rate Hike Decisions Amid Geopolitical Tensions and Inflation Concerns.

2026. g. 31. aug. 23:52 UTC

U.S. Initial Jobless Claims Expected at 205K Amid Inflation Concerns and Fed Rate Hike Speculation

2026. g. 31. aug. 23:52 UTC

Japan's Q2 2026 GDP Growth Rate Expected at 0.3%, Sparking Speculation of Interest Rate Hike Amid Mixed Economic Sentiment

2026. g. 31. aug. 23:52 UTC

Japan's Q2 2026 GDP Growth Release Expected at 1.1% Amid Mixed Economic Signals and Potential BoJ Interest Rate Hikes

2026. g. 31. aug. 23:51 UTC

Enterprise Financial Services Corp shares are lower in after-market trading, lacking any specific news to explain the decline. The stock remains below its 20-day moving average.

2026. g. 31. aug. 23:51 UTC

Dyadic International Inc shares are higher in after-market hours, showing strong buying interest despite a recent significant decline and downward pressure over the past sessions.

2026. g. 31. aug. 23:51 UTC

Wayfair Inc shares are lower in after-market trading, reversing a trend of higher daily closes. No specific news was identified to explain the decline.

2026. g. 31. aug. 23:51 UTC

United Parks & Resorts Inc. shares are higher in after-market trading, reflecting notable strength despite no specific company news identified.

2026. g. 31. aug. 23:51 UTC

Playtika Holding Corp shares are higher in after-market trading. No specific news was identified to explain this movement amid broader market volatility.

2026. g. 31. aug. 23:51 UTC

European equity markets decline amid rising oil prices and inflation concerns following U.S.-Iran military tensions, with investors cautious ahead of key economic data.

2026. g. 31. aug. 23:51 UTC

U.S. equity indices decline amid rising oil prices and geopolitical tensions, with Fed rate hike expectations intensifying.

2026. g. 31. aug. 23:51 UTC

Asia equity markets mixed as Middle East tensions and hawkish Fed signals drive oil prices up and investor caution.

2026. g. 31. aug. 23:51 UTC

U.S. and European markets decline amid rising oil prices and inflation fears following U.S.-Iran tensions, while Dallas Fed Manufacturing Index signals strong recovery.

2026. g. 31. aug. 23:51 UTC

Helmerich and Payne Inc. shares are higher in after-market trading, supported by a rise in Brent crude futures amid geopolitical tensions in the Strait of Hormuz.

Salīdzinājums

Cenas izmaiņa

Zentalis Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

132.37% augšup

Prognoze 12 mēnešiem

Vidējais 8.83 USD  132.37%

Augstākais 11 USD

Zemākais 5 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

6 ratings

5

Pirkt

1

Turēt

0

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat